Johnson & Johnson Financial Statements
NYSE: JNJHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Johnson & Johnson revenue and earnings
In fiscal 2025, Johnson & Johnson generated $94.19 billion in revenue, up 6.0% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $26.80 billion (+90.6% year over year), for a net margin of 28.5% versus a median of 22.4% in the prior 5 years. Gross margin was 67.9% (down from 69.1%).
Diluted earnings per share came in at $11.03, up from $5.79. Over the last 5 fiscal years, JNJ's revenue has grown at a 2.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Johnson & Johnson income statement (annual)
| Fiscal year (USD) | FY 20252025-12-28 | FY 20242024-12-29 | FY 20232023-12-31 | FY 20222023-01-01 | FY 20212022-01-02 | FY 20202021-01-03 | FY 20192019-12-29 | FY 20182018-12-30 | FY 20172017-12-31 | FY 20162017-01-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B |
| Revenue growth (YoY) | +6.05% | +4.30% | +6.46% | +1.59% | -4.65% | +0.64% | +0.59% | +6.71% | +6.34% | +2.59% |
| Cost of Revenue | 30.26B | 27.47B | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B | 27.09B | 25.44B | 21.79B |
| Gross Profit | 63.94B | 61.35B | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B | 54.49B | 51.01B | 50.10B |
| Research & Development | 109.00M | 1.84B | 483.00M | 0 | 0 | 12.16B | 11.36B | 10.78B | 10.59B | 9.14B |
| Selling, General & Admin | 23.68B | 22.87B | 21.51B | 20.25B | 20.12B | 22.08B | 22.18B | 22.54B | 21.52B | 20.07B |
| Interest Expense | 971.00M | 755.00M | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M | 1.00B | 934.00M | 726.00M |
| Other Income (Expense) | 7.21B | -4.69B | -6.63B | -810.00M | -526.00M | -2.90B | -2.52B | -1.41B | 42.00M | -210.00M |
| Pretax Income | 32.58B | 16.69B | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B | 18.00B | 17.67B | 19.80B |
| Income Tax | 5.78B | 2.62B | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.37B | 3.26B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B |
| Net Income growth (YoY) | +90.56% | -59.99% | +95.94% | -14.07% | +41.89% | -2.68% | -1.16% | +1076.69% | -92.14% | +7.34% |
| EPS (Basic) | 11.13 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.72 | 5.70 | 0.48 | 6.04 |
| EPS (Diluted) | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 |
| Shares Outstanding (Basic) | 2.41B | 2.41B | 2.53B | 2.63B | 2.63B | 2.63B | 2.65B | 2.68B | 2.69B | 2.74B |
| Shares Outstanding (Diluted) | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B |
| Gross Margin | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% |
| Net Margin | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% |
This table shows 10 annual periods of Johnson & Johnson's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow JNJ's reporting calendar. What is a income statement?